1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Soft Tisue Sarcoma (STS) with lung metastases - Epidemiology Forecast to 2030

Soft Tisue Sarcoma (STS) with lung metastases - Epidemiology Forecast to 2030

  • January 2021
  • 80 pages
  • ID: 6010478
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Soft Tisue Sarcoma (STS) with lung metastases—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

STS with lung metastases Disease Understanding
Soft tissue sarcoma is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. The lung is the most frequent site of metastasis from soft-tissue sarcomas. From several studies, it has been estimated that around 50–60% of the STS cases develop lung metastases.

STS with lung metastases Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

STS with lung metastases Detailed Epidemiology Segmentation
• As per The analyst estimates, the incident cases of STS with lung metastases in the 7MM was 7,871 cases in 2017.
• Among the EU5, Germany had the highest incident population in 2017 (1,308 cases), followed by France
• Females accounted for a larger percentage among the STS with lung metastases cases as compared to males. In 2017, a lower number of males were affected by this disease, i.e., 42% of the total incident cases of STS with lung metastases population in the United States, which is equivalent to 1,053 cases. In comparison to this, for females, the number of cases observed was 1,454 in 2017.
• Among the total incidence of STS with lung metastases cases in the United States, there were 777 cases of Leiomyosarcoma, and 150 cases of liposarcoma, followed by synovial with 376 cases and other types with 1,203 cases.
• The incident population of STS with lung metastases in Japan is increasing at a CAGR rate of 1.18%, during the study period

Scope of the Report
• The report covers the descriptive overview of STS with lung metastases, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of STS with lung metastases.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases.

Report Highlights
• 11-Year Forecast of STS with lung metastases
• 7MM Coverage
• Total incident cases of Soft tissue sarcoma
• Total incident cases of STS with lung metastases
• Gender-specific incident cases of STS with lung metastases
• Subtype-specific incident cases of STS with lung metastases

Key Questions Answered
• What is the disease risk, burden, and unmet needs of STS with lung metastases?
• What is the historical STS with lung metastases patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of STS with lung metastases at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to STS with lung metastases?
• Out of the above-mentioned countries, which country would have the highest incident population of STS with lung metastases during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The STS with lung metastases report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM STS with lung metastases epidemiology forecast.
• The STS with lung metastases epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The STS with lung metastases epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Melanoma - Epidemiology Forecast to 2029

  • $ 3995
  • April 2021
  • 41 pages

Melanoma - Epidemiology Forecast to 2029 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World ...

  • World
  • Cancer
  • Healthcare
  • Industry analysis
  • Cancer Incidence
  • Health Provider Density

Global Sarcoma Drugs Industry $ 5600 April 2021

Global Kaposi Sarcoma Industry $ 4950 April 2021


ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on